Ensoma
Rob Peters brings to Ensoma more than 20 years of research and development experience, including working on recombinant clotting Factor VIII and Factor IX Fc fusion proteins from their inception in research through manufacturing, clinical development and supporting market launch as Eloctate/Elocta and Alprolix, the first extended half-life clotting factors for the treatment of hemophilia A and B, respectively.
This person is not in any offices
Ensoma
1 followers
Ensoma believes every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of their Engenious™ vectors, their therapies can be delivered in a simple, single injection.